市場調査レポート

商品コード

1085790

ピラジナミドの世界市場：患者タイプ、流通チャネル、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年）

Pyrazinamide Market, by Patient Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: 2022年05月10日 | 発行: Coherent Market Insights

| ページ情報: 英文 149 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 700,920円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,090,320円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,557,600円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.76円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界的な結核の負担増大、結核治療に対する医療費増加が、ピラジナミド市場の成長を促進すると期待されます。しかし、結核治療の新規治療法開発のための研究開発活動への増資が、ピラジナミド薬市場の成長を抑制すると予測されます。

当レポートでは、世界のピラジナミド市場について調査分析し、市場概要、市場力学、動向、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

Pyrazinamide (PZA) is a medication used to treat tuberculosis. Moreover, for active tuberculosis, it is often used with rifampicin, isoniazid, and either streptomycin or ethambutol. It is not generally recommended for the treatment of latent tuberculosis. Pyrazinamide kills non-replicating persister cells that other medication of TB fail to kill, and for which it became important drug for inclusion in any drug combinations for treating drug susceptible and drug-resistant TB such as MDR-TB. It acts variably compared to other antibiotics by inhibiting energy production, trans-translation, and co-enzyme A required for persister survival. The increasing mutation in drug targeted gene is marking bacterial strain more resistant to PZA drug. The recently panD mutations gene was found along with pncA or rpsA mutations gene in bacterial resistant strains.

Market Dynamics

The high burden of TB is expected to drive growth of the market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa, which accounted for two thirds of the new TB cases.

The increasing global burden of TB is expected to drive the pyrazinamide market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.

Moreover, according to the WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$ 12 billion in additional economic costs and lost productivity. Thus, increasing healthcare spending on treatment of TB is expected to drive growth of the market.

Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.

Moreover, increasing investments in R&D activities for development of novel therapies for treatment of TB is expected to restrain growth of the pyrazinamide drugs market. For instance, according to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017, with an increase of 6% (or US$ 46 million), compared to US$ 726 million in 2016.

Key features of the study:

This report provides in-depth analysis of the global pyrazinamide market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
It profiles key players in the global pyrazinamide market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global pyrazinamide market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of Infertility drugs and devices, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Pyrazinamide Market, By Patient Type:
- Adult
- Pediatric
Global Pyrazinamide Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Pyrazinamide Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
  - By Patient Type:
- Adult
- Pediatric
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
  - By Patient Type:
- Adult
- Pediatric
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
  - By Patient Type:
- Adult
- Pediatric
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
  - By Patient Type:
- Adult
- Pediatric
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
  - By Patient Type:
- Adult
- Pediatric
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
  - By Patient Type:
- Adult
- Pediatric
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
  - Pure Chemistry Scientific*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
  - LGM Pharma
  - City Chemical
  - TCI
  - HBCChem
  - Alfa Chemistry
  - Toronto Research Chemicals
  - Acros Organics
  - AlliChem
  - Waterstone Technology

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Patient Type
- Market Snapshot, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Market Trends
Key Developments
Impact Analysis
Mergers & Acquisitions
New Product Launch
Technology Overview
PEST Analysis

4. Global Pyrazinamide Market - Impact of Coronavirus (Covid-19) Pandemic

COVID 19 Impact Analysis
New Developments

5. Global Pyrazinamide Market, By Patient Type, 2017 - 2028, (US$ million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Pyrazinamide Market, By Distribution Channel, 2017 - 2028, (US$ million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Pyrazinamide Market, By Region, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, By Patient Type, 2022 and 2028 (%)
- Market Share Analysis, By Distribution Channel, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
North America
- Market Share Analysis, By Patient Type, 2022 and 2028 (%)
- Market Share Analysis, By Distribution Channel, 2022 and 2028 (%)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
Europe
- Market Share Analysis, By Patient Type, 2022 and 2028 (%)
- Market Share Analysis, By Distribution Channel, 2022 and 2028 (%)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Share Analysis, By Patient Type, 2022 and 2028 (%)
- Market Share Analysis, By Distribution Channel, 2022 and 2028 (%)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Market Share Analysis, By Patient Type, 2022 and 2028 (%)
- Market Share Analysis, By Distribution Channel, 2022 and 2028 (%)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East
- Market Share Analysis, By Patient Type, 2022 and 2028 (%)
- Market Share Analysis, By Distribution Channel, 2022 and 2028 (%)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Share Analysis, By Patient Type, 2022 and 2028 (%)
- Market Share Analysis, By Distribution Channel, 2022 and 2028 (%)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa

8. Competitive Landscape

Company Profiles
- Pure Chemistry Scientific
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- LGM Pharma
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- City Chemical
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- TCI
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- HBCChem
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Alfa Chemistry
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Toronto Research Chemicals
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Acros Organics
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AlliChem
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Waterstone Technology
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies

9. Section

References
Research Methodology
About Us and Sales Contact

ピラジナミドの世界市場：患者タイプ、流通チャネル、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年）

Pyrazinamide Market, by Patient Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章調査目的・前提条件

第2章市場概要

第3章市場力学・規制・動向分析

第4章世界のピラジナミド市場：コロナウイルス（COVID-19）パンデミックの影響

第5章世界のピラジナミド市場：患者タイプ別（2017年～2028年）

第6章世界のピラジナミド市場：流通チャネル別（2017年～2028年）

第7章世界のピラジナミド市場：地域別（2017年～2028年）

第8章競合情勢

第9章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Pyrazinamide Market - Impact of Coronavirus (Covid-19) Pandemic

5. Global Pyrazinamide Market, By Patient Type, 2017 - 2028, (US$ million)

6. Global Pyrazinamide Market, By Distribution Channel, 2017 - 2028, (US$ million)

7. Global Pyrazinamide Market, By Region, 2017 - 2028, (US$ Million)

8. Competitive Landscape

9. Section

ピラジナミドの世界市場：患者タイプ、流通チャネル、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年）

Pyrazinamide Market, by Patient Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・規制・動向分析

第4章 世界のピラジナミド市場：コロナウイルス（COVID-19）パンデミックの影響

第5章 世界のピラジナミド市場：患者タイプ別（2017年～2028年）

第6章 世界のピラジナミド市場：流通チャネル別（2017年～2028年）

第7章 世界のピラジナミド市場：地域別（2017年～2028年）

第8章 競合情勢

第9章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Pyrazinamide Market - Impact of Coronavirus (Covid-19) Pandemic

5. Global Pyrazinamide Market, By Patient Type, 2017 - 2028, (US$ million)

6. Global Pyrazinamide Market, By Distribution Channel, 2017 - 2028, (US$ million)

7. Global Pyrazinamide Market, By Region, 2017 - 2028, (US$ Million)

8. Competitive Landscape

9. Section

第1章調査目的・前提条件

第2章市場概要

第3章市場力学・規制・動向分析

第4章世界のピラジナミド市場：コロナウイルス（COVID-19）パンデミックの影響

第5章世界のピラジナミド市場：患者タイプ別（2017年～2028年）

第6章世界のピラジナミド市場：流通チャネル別（2017年～2028年）

第7章世界のピラジナミド市場：地域別（2017年～2028年）

第8章競合情勢

第9章セクション